Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company that researches and develops medicines for the treatment of cystic fibrosis (CF). Its pipeline includes galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed CFTR corrector that has completed a Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed a Phase 2 trial; SION-109, an intracellular loop 4-directed CFTR corrector that has completed a Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed a Phase 1 trial; SION-451, a nucleotide-binding domain 1 stabilizer in a Phase 1 trial; and SION-719, a nucleotide-binding domain 1 stabilizer in a Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. It was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Why is Sionna Therapeutics, Inc. Common Stock (SION) moving?
Latest
▼3▲1
Sionna's lead CF drug failed; now it's cutting costs and betting on a backup
▼
Lead cystic fibrosis drug failed its key trial SION-719, Sionna's main drug, did not meaningfully improve CFTR function in a Phase 2a trial — the sweat chloride change was tiny and not statistically significant. The company dropped it as a Trikafta add-on. Since the stock's value rested on this drug, shares collapsed over 90%.
This is the single biggest force behind SION's move and the root cause of everything that followed.
Rival Vertex strengthened as Sionna's threat faded With Sionna's add-on approach shelved, Vertex's dominant cystic fibrosis franchise faces less competition, and Vertex shares hit new highs. That matters for Sionna because the market now sees a harder path to winning any share of the CF market.
It explains the competitive backdrop that makes Sionna's setback worse for its long-term value.
46% workforce cut to save cash after the failure Sionna is cutting nearly half its staff, costing about $6.4 million, to lower spending and stretch its cash into the second half of 2029. It's a sign of retrenchment, but it also buys time to develop the backup program.
It shows the concrete financial and operational fallout of the trial failure, which drives the stock lower.
Backup combo shows promise ahead of 2027 trial Sionna is now focused on SION-451 plus SION-2222, which it will test in the AscenSION Phase 2a trial starting early 2027. New preclinical data showed these NBD1 stabilizers improved CFTR function up to normal levels, offering a possible path forward.
It is the main counterweight — the remaining reason investors see any value in Sionna after the failure.
Sionna Therapeutics to Present Cystic Fibrosis Data at 2026 NACFC
Sionna Therapeutics announced it will present new data on its NBD1 stabilizers at the 2026 North American Cystic Fibrosis Conference in Atlanta, Georgia, held October 7-10, 2026. The oral presentation covers previously disclosed post hoc analyses of the PreciSION CF Phase 2a trial of SION-719 added to Trikafta; although the trial missed its key activity endpoint, analyses excluding three participants with PK patterns consistent with dosing non-adherence showed a mean placebo-adjusted sweat chloride reduction of 8.6 mmol/L, and identified lower exposures of all three Trikafta components plus a potential interaction between SION-719 and the potentiator ivacaftor. Sionna said these findings, together with favorable Phase 1 safety, tolerability and PK results, support advancing SION-451 plus SION-2222 into AscenSION CF, an open-label, 28-day Phase 2a proof-of-concept trial assessing sweat chloride, safety and PK in adults with CF homozygous for F508del, expected to begin in the first quarter of 2027. A poster presents preclinical data showing that NBD1 stabilizers SION-451 and SION-719, in combination with complementary modulators including SION-2222 and SION-109, improved CFTR trafficking and function up to wild-type levels across primary human bronchial epithelial cells from F508del/F508del and F508del/null donors, supporting their potential to benefit a broad population of people with CF.
Biotech & Genomic Medicine › Rare Disease Technology
SION · Technology · Positive Sionna will present new NBD1 stabilizer data at NACFC 2026, with preclinical results showing CFTR function improved up to wild-type levels, supporting advancement of SION-451 plus SION-2222 into the AscenSION CF Phase 2a trial.
Sionna to Cut 46% of Workforce After CF Study Failure
Sionna Therapeutics will cut about 46% of its workforce after its cystic fibrosis pipeline suffered a key clinical setback, sending SION shares down nearly 17% yesterday. The restructuring, which Sionna expects to cost approximately $6.4 million, is aimed at lowering operating expenses and focusing resources on its prioritized CF programs, and the company says the measures should extend its cash runway into the second half of 2029. The move follows disappointing results for SION-719, a nucleotide binding domain 1 stabilizer tested as an add-on to Vertex Pharmaceuticals' marketed CF treatment Trikafta in adults homozygous for the F508del mutation; the phase IIa PreciSION CF proof-of-concept study missed its key endpoint, failing to show a statistically significant reduction in sweat chloride levels, and Sionna decided not to continue developing the candidate as a Trikafta add-on. A post-hoc analysis that excluded three participants showed a placebo-adjusted sweat chloride reduction of 8.6 mmol/L, but the company noted this was not the prespecified primary analysis and is therefore less conclusive. Sionna is now concentrating on its proprietary dual combination of SION-451 and SION-2222, which it selected as its preferred combination after a phase I study met safety, tolerability and pharmacokinetic objectives, and it intends to advance the pair into the phase IIa AscenSION CF proof-of-concept study in the first quarter of 2027. Year to date, SION's stock has plunged 83.3% against the industry's 7.8% growth.
Sionna’s CF Drug Fails, Vertex Rallies to New Highs
Sionna Therapeutics shares plunged more than 90% after its lead cystic fibrosis drug candidate SION-719 failed a Phase 2a trial, while Vertex Pharmaceuticals surged to new highs as a key competitive threat was removed. The trial, which tested SION-719 as an add-on to Vertex’s blockbuster Trikafta regimen, did not meet its main activity endpoint, and Sionna will not advance the program. Sionna will now prioritize an earlier-stage SION-451 combo program, but with over $268 million in cash and its lead asset shelved, the stock’s valuation was heavily dependent on SION-719. Vertex, already trading near record levels after raising full-year revenue guidance and proposing a $10 billion acquisition of Crinetics Pharmaceuticals, saw its cystic fibrosis dominance further de-risked.
Several stocks made significant midday moves on Monday. MarineMax soared 46% after agreeing to be sold to Blackstone Infrastructure's Safe Harbor Marinas for $53 a share in cash, or $1.5 billion, with the deal expected to close by the end of 2026. Varex Imaging climbed 48% after Teledyne Technologies agreed to buy the imaging component maker for $18.90 a share in cash, a deal expected to close in early 2027. Sionna Therapeutics collapsed 92% after its cystic fibrosis drug failed to meet key endpoints in a proof-of-concept trial, and the company said it would not advance the drug. Other notable movers included NetApp, which gained 6% after Morgan Stanley upgraded it to equal weight from underweight, and Verisk Analytics, which tumbled more than 5% after a Delaware judge ruled it must proceed with a $2.35 billion acquisition of AccuLynx. Apple dipped 2% after Jefferies downgraded the stock to underperform from hold, citing canceled plans for an all-glass iPhone. Intel fell nearly 3% after announcing a $15 billion common stock offering for general corporate purposes.
Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails
Vertex Pharmaceuticals shares surged approximately 5.9% in Monday's regular session after Sionna Therapeutics announced its drug SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is dropping that specific add-on strategy, giving Vertex's dominant cystic-fibrosis franchise more breathing room. Vertex's second-quarter revenue climbed 12% to roughly $3.33 billion, and management raised full-year revenue guidance to $13.1 billion to $13.2 billion. Despite the stock's jump, GuruFocus estimates Vertex's GF Value at $519.20, leaving the shares trading only 1.34% above that fair value estimate at $526.15.
Biotech & Genomic Medicine › Rare Disease ▲Competition
SION · Technology · Negative Sionna's drug SION-719 missed the key activity endpoint in a Phase 2a trial, and the company is dropping that add-on strategy.
VRTX · Competition · Positive Rival Sionna's drug failure reduces competitive threat to Vertex's cystic fibrosis franchise.
VRTX · Capital · Positive Vertex raised full-year revenue guidance to $13.1-13.2 billion after Q2 revenue climbed 12%.
Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout
Tenax Therapeutics and Sionna Therapeutics shares plunged in premarket trading after their respective clinical trials failed, while MarineMax jumped on a reported buyout by Blackstone-owned Safe Harbor Marinas. Tenax stock fell 84.2% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, showing no statistically significant improvement in six-minute walk distance versus placebo with a p-value of 0.63. Sionna shares dropped 92.1% after its Phase 2a trial of SION-719 failed to demonstrate meaningful CFTR function improvement, with a placebo-adjusted sweat chloride change of just -1.0 mmol/L and a p-value of 0.7. MarineMax surged more than 34% after Reuters reported Safe Harbor is close to acquiring the boat retailer for $1.5 billion including debt, or about $53 per share in cash, a substantial premium to Friday's close of $35.68. AAON gained over 10.6% after its second-quarter results apparently beat expectations, while Silence Therapeutics rose 16.2% ahead of a conference call on its Phase 2 SANRECO trial. Dole fell 4.2% after missing second-quarter earnings and revenue estimates, and AirSculpt Technologies dropped 18.4% on weaker quarterly results with revenue down 3% year-over-year.
USA